Tyson Foods Plant Fire in Georgia Claims Life, Injures Several Workers After Boiler Explosion 
Exercise boosts memory for up to 24 hours after a workout – new research 
Elon Musk Sparks Outrage Claiming 'Newsrooms Illegal for Republicans' in Wake of Shocking Journalist Data 
Elon Musk’s X Money Launch Set to Revolutionize Digital Payments and Dominate 2025’s Fintech World 
Brad Pitt and Angelina Jolie End an Eight-Year Divorce Saga in Shocking Christmas Resolution 
Explosive CIA Whistleblower Claims Havana Syndrome Victims Face Cancer, Dementia, and Government Betrayal 
‘A Shocking Divide!’ COVID Vaccine Poll Shows Republicans Say ‘No Way’ While Democrats Roll Up Sleeves 
Russian Air Defense System Blamed for Azerbaijan Airlines Crash Killing 38 in Tragic Turn of Events 
We don’t all need regular skin cancer screening – but you can know your risk and check yourself 
Putin Drives Russia's Government and Top Bank to Strengthen AI Cooperation with China Amid Sanctions 
Why bovine colostrum supplements could be a health gamble 
Biden’s ‘Shocking’ Clemency Frees Florida Killers in Escobedo Family Slaying, Sparks Outrage Nationwide 
Ex-CDC Director Says ‘Vaccine Makers Lied’ About COVID as He Urges Congress to End Liability Shield 
Wall Street Tumbles with Dow Plunging 505 Points as Nasdaq Locks Longest Winning Streak Since 2021 
Puerto Rico in Darkness Again as Grid Failure Hits New Year’s Eve Festivities 
Venezuela Tops 9% Economic Growth in 2024 with Hydrocarbons Boosting a Historic Recovery Year 
A gold rush for ‘green finance’ risks changing our relationship to nature 
Bristol Myers Squibb has sued AstraZeneca for its antibody-based cancer treatment Imjudo, which it says infringes its patents for its drug Yervoy
According to Bristol Myer, Imjudo fights cancer in the same way as Yervoy.
Bristol Myers has previously sued AstraZeneca for patent infringement over the latter’s other cancer drug, Imfinzi.
AstraZeneca said it is aware of the complaint and will respond to it "at the appropriate time."
The FDA has also approved the immunotherapy Yervoy for the treatment of kidney, lung, colorectal, and other cancers. The FDA initially approved Yervoy in 2011 to treat melanoma.
In 2021, Bristol Myers sold over $2 billion worth of Yervoy.
AstraZeneca’s Imjudo was given FDA approval last year to be used in conjunction with Imfinzi to treat liver and lung cancer.
In the second lawsuit, Bristol Myers claimed that AstraZeneca had violated two patents on the use of antibodies to treat cancer and strengthen a patient's immune system.
Bristol Myers insists that AstraZeneca was aware of the patents, being on notice due to licensing discussions and the Imfinzi lawsuit.
The lawsuit seeks an unspecified amount of money for damages.
